The Children's Hospital of Philadelphia (CHOP) and BGI-Shenzhen recently announced an agreement to collaborate on research into next-generation sequencing and analysis of pediatric brain tumors, in support of the Childhood Brain Tumor Tissue Consortium (CBTTC). The research initiative will draw on the resources of the state-of-the-art Joint Genome Center BGI@CHOP, which provides next-generation sequencing under CAP/CLIA guidelines, the gold standard of quality in clinical laboratory testing.

A collaborative pediatric research group that brings together four institutions, the CBTTB is made up of The Children's Hospital of Philadelphia (which houses the consortium's operations center), the Children's Hospital of Pittsburgh, Seattle Children's Hospital, and Lurie Children's Hospital of Chicago. The consortium is dedicated to the collection, annotation, and molecular analyses of children's brain tumors.

Next-generation sequencing of pediatric brain tumors offers a deep and comprehensive view into the genetic underpinnings of these often-devastating solid tumors. In collaboration with BGI's genomics platforms, the new project will support the development of new and more effective forms of therapy targeted to each patient's specific subtype of brain tumor.

"These important efforts are made possible through the further extension of CHOP's productive collaboration with BGI, a world-class institution in the global genome sequencing arena that is using its scientific expertise and technological know-how to improve medical research," said Tom Curran, PhD, FRS, deputy science director of CHOP Research.

"BGI is pleased to have deepened its relationship with The Children's Hospital of Philadelphia, a global leader in pediatric care and research," said Dr. Jun Wang, executive director of BGI-Shenzhen. "We look forward to a productive partnership that will accelerate advances in the research and treatment of pediatric brain tumors."